| Active ingredients | Dosage form | Quantity of active ingredients | Shortage status | Availability | Reason | Last updated |
| tramadol hydrochloride | Capsule | 50 mg | Resolved | Available | Manufacturing | 10/10/2025 |
| topiramate | Tablet, film coated | 50 mg | Anticipated | Available | Manufacturing | 10/10/2025 |
| ciprofloxacin hydrochloride | Tablet, film coated | 832.5 mg | Anticipated | Available | Manufacturing | 10/10/2025 |
| tetrabenazine | Tablet, uncoated | 25 mg | Resolved | Available | Manufacturing | 10/10/2025 |
| venlafaxine hydrochloride | Capsule, modified release | 169.71 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 10/10/2025 |
| fosaprepitant dimeglumine | Injection, powder for | 257.6 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 10/10/2025 |
| temozolomide | Capsule, hard | 5 mg | Current | Limited Availability | Manufacturing | 10/10/2025 |
| galantamine hydrobromide | Capsule, modified release | 20.504 mg | Current | Unavailable | Manufacturing | 10/10/2025 |
| galantamine hydrobromide | Capsule, modified release | 30.756 mg | Current | Unavailable | Manufacturing | 10/10/2025 |
| montelukast sodium | Tablet, chewable | 4.16 mg | Current | Unavailable | Manufacturing | 10/10/2025 |
| raloxifene hydrochloride | Tablet, film coated | 60 mg | Current | Unavailable | Manufacturing | 10/10/2025 |
| quetiapine fumarate | Tablet, film coated | 115.12 mg | Anticipated | Available | Commercial Changes / Commercial viability | 10/10/2025 |
| quetiapine fumarate | Tablet, film coated | 345.36 mg | Anticipated | Available | Commercial Changes / Commercial viability | 10/10/2025 |
| cisatracurium besilate | Injection, solution | 7.04 mg | Current | Limited Availability | Manufacturing | 10/10/2025 |
| mebeverine hydrochloride | Tablet, film coated | 135 mg | Current | Unavailable | Manufacturing | 10/10/2025 |
| ropinirole hydrochloride | Tablet, film coated | .285 mg | Current | Unavailable | Manufacturing | 10/10/2025 |
| lacosamide | Tablet, film coated | 150 mg | Current | Limited Availability | Manufacturing | 10/10/2025 |
| Trastuzumab | Injection, powder for | 156 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 10/10/2025 |
| teriflunomide | Tablet, film coated | 14 mg | Current | Limited Availability | Manufacturing | 10/10/2025 |
| rivaroxaban | Tablet, film coated | 10 mg | Anticipated | Available | Manufacturing | 10/10/2025 |
| valaciclovir hydrochloride | Tablet, film coated | 1112 mg | Current | Limited Availability | Manufacturing | 10/10/2025 |
| phenoxymethylpenicillin potassium | Oral Liquid, powder for | 28.284 mg/mL | Current | Unavailable | Manufacturing | 9/10/2025 |
| lansoprazole | Tablet, orally disintegrating | 30 mg | Current | Limited Availability | Manufacturing | 9/10/2025 |
| chloramphenicol | Eye Drops | 5 mg/mL | Resolved | Available | Manufacturing | 9/10/2025 |
| lansoprazole | Tablet, orally disintegrating | 15 mg | Current | Unavailable | Manufacturing | 9/10/2025 |
| desvenlafaxine | Tablet, modified release | 100 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 9/10/2025 |
| desvenlafaxine | Tablet, modified release | 50 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 9/10/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .125 mg | Current | Unavailable | Unexpected increase in consumer demand | 9/10/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .25 mg | Current | Unavailable | Unexpected increase in consumer demand | 9/10/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | 1 mg | Anticipated | Available | Manufacturing | 9/10/2025 |
| hydrocortisone | Tablet, uncoated | 4 mg | Anticipated | Available | Manufacturing | 9/10/2025 |
| ezetimibe~simvastatin | Tablet | 10 mg~40 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 9/10/2025 |
| fingolimod hydrochloride | Capsule | 560 microgram | Anticipated | Available | Manufacturing | 9/10/2025 |
| estradiol | Drug delivery system, transdermal | .39 mg | Current | Unavailable | Manufacturing | 9/10/2025 |
| estradiol | Drug delivery system, transdermal | .78 mg | Current | Unavailable | Manufacturing | 9/10/2025 |
| estradiol | Drug delivery system, transdermal | 1.17 mg | Current | Unavailable | Manufacturing | 9/10/2025 |
| estradiol | Drug delivery system, transdermal | 1.56 mg | Current | Unavailable | Manufacturing | 9/10/2025 |
| lenalidomide | Capsule | 5 mg | Current | Limited Availability | Manufacturing | 9/10/2025 |
| bleomycin sulfate | Injection, powder for | 15000 IU | Anticipated | Available | Manufacturing | 9/10/2025 |
| doxorubicin hydrochloride | Injection, concentrated | 20 mg | Resolved | Available | Manufacturing | 9/10/2025 |
| methylphenidate hydrochloride | Tablet, modified release | 18 mg | Current | Limited Availability | Manufacturing | 9/10/2025 |
| methylphenidate hydrochloride | Tablet, modified release | 36 mg | Current | Limited Availability | Manufacturing | 9/10/2025 |
| tranexamic acid | Tablet, film coated | 500 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 8/10/2025 |
| galantamine hydrobromide | Capsule, modified release | 30.768 mg | Current | Unavailable | Unexpected increase in demand due to other sponsors unable to supply | 8/10/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .25 mg | Current | Unavailable | Transport / Logistic issues / Storage capacity issues | 8/10/2025 |
| pramipexole dihydrochloride monohydrate | Tablet | .125 mg | Current | Unavailable | Manufacturing | 8/10/2025 |
| valsartan~hydrochlorothiazide | Tablet, film coated | 320 mg~25 mg | Resolved | Available | Manufacturing | 8/10/2025 |
| temozolomide | Capsule, hard | 20 mg | Anticipated | Available | Manufacturing | 8/10/2025 |
| escitalopram oxalate | Tablet, film coated | 25.548 mg | Anticipated | Available | Manufacturing | 8/10/2025 |
| lansoprazole | Tablet, orally disintegrating | 30 mg | Current | Unavailable | Manufacturing | 8/10/2025 |
| anastrozole | Tablet, film coated | 1 mg | Current | Limited Availability | Manufacturing | 8/10/2025 |
| clonidine hydrochloride | Tablet | 100 microgram | Resolved | Available | Manufacturing | 8/10/2025 |
| hydrochlorothiazide~irbesartan | Tablet, film coated | 12.5 mg~150 mg | Current | Unavailable | Manufacturing | 8/10/2025 |
| hydrochlorothiazide~irbesartan | Tablet, film coated | 25 mg~300 mg | Current | Unavailable | Manufacturing | 8/10/2025 |
| metformin hydrochloride | Tablet, film coated | 1000 mg | Current | Unavailable | Unexpected increase in consumer demand | 8/10/2025 |
| Mecasermin | Injection, solution | 10 mg/mL | Resolved | Available | Unexpected increase in consumer demand | 8/10/2025 |
| erlotinib hydrochloride | Tablet, film coated | 27.32 mg | Current | Unavailable | Unexpected increase in consumer demand | 8/10/2025 |
| spironolactone | Tablet, uncoated | 25 mg | Resolved | Available | Manufacturing | 8/10/2025 |
| bortezomib | Injection, solution | 3.5 mg | Resolved | Available | Manufacturing | 8/10/2025 |
| paracetamol | Tablet, modified release | 665 mg | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 8/10/2025 |
| naproxen | Tablet, uncoated | 250 mg | Resolved | Available | Manufacturing | 8/10/2025 |
| tranexamic acid | Tablet, film coated | 500 mg | Anticipated | Available | Unexpected increase in demand due to other sponsors unable to supply | 8/10/2025 |
| trandolapril | Capsule, hard | 2 mg | Resolved | Available | Manufacturing | 8/10/2025 |
| rifampicin | Capsule, hard | 300 mg | Current | Unavailable | Manufacturing | 8/10/2025 |
| clindamycin phosphate | Cream | 22.8 mg/g | Resolved | Available | Transport / Logistic issues / Storage capacity issues | 8/10/2025 |
| paclitaxel | Injection, concentrated | 6 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 8/10/2025 |
| labetalol hydrochloride | Tablet, film coated | 100 mg | Current | Limited Availability | Manufacturing | 8/10/2025 |
| dosulepin hydrochloride | Tablet, film coated | 75 mg | Current | Limited Availability | Manufacturing | 8/10/2025 |
| metformin hydrochloride | Tablet, film coated | 1000 mg | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 8/10/2025 |
| acetylcysteine | Injection, concentrated | 2 g | Current | Limited Availability | Manufacturing | 7/10/2025 |
| topiramate | Tablet, film coated | 25 mg | Current | Unavailable | Manufacturing | 7/10/2025 |
| ciprofloxacin hydrochloride | Tablet, film coated | 277.5 mg | Current | Unavailable | Manufacturing | 7/10/2025 |
| acetazolamide sodium | Injection, powder for | 549.5 mg | Current | Unavailable | Manufacturing | 7/10/2025 |
| lamotrigine | Tablet, chewable | 50 mg | Anticipated | Available | Manufacturing | 7/10/2025 |
| lamotrigine | Tablet, chewable | 100 mg | Current | Unavailable | Manufacturing | 7/10/2025 |
| olanzapine | Tablet, film coated | 5 mg | Current | Unavailable | Manufacturing | 7/10/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 10 mg | Current | Limited Availability | Manufacturing | 7/10/2025 |
| levetiracetam | Tablet, film coated | 500 mg | Current | Limited Availability | Manufacturing | 7/10/2025 |
| sildenafil citrate | Tablet, film coated | 140.45 mg | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 7/10/2025 |
| sulfamethoxazole~trimethoprim | Tablet, uncoated | 800 mg~160 mg | Resolved | Available | Manufacturing | 7/10/2025 |
| exemestane | Tablet, sugar coated | 25 mg | Anticipated | Available | Manufacturing | 7/10/2025 |
| olanzapine | Tablet, orally disintegrating | 10 mg | Anticipated | Available | Manufacturing | 7/10/2025 |
| olanzapine | Tablet, orally disintegrating | 5 mg | Anticipated | Available | Manufacturing | 7/10/2025 |
| atorvastatin calcium trihydrate | Tablet, film coated | 21.69 mg | Current | Unavailable | Manufacturing | 7/10/2025 |
| atorvastatin calcium trihydrate | Tablet, film coated | 43.38 mg | Anticipated | Available | Manufacturing | 7/10/2025 |
| galantamine hydrobromide | Capsule, modified release | 10.252 mg | Current | Unavailable | Manufacturing | 7/10/2025 |
| galantamine hydrobromide | Capsule, modified release | 30.756 mg | Current | Unavailable | Manufacturing | 7/10/2025 |
| galantamine hydrobromide | Capsule, modified release | 20.504 mg | Current | Unavailable | Manufacturing | 7/10/2025 |
| indapamide hemihydrate | Tablet, sugar coated | 2.5 mg | Current | Limited Availability | Manufacturing | 7/10/2025 |
| montelukast sodium | Tablet, chewable | 4.16 mg | Current | Unavailable | Manufacturing | 7/10/2025 |
| isotretinoin | Capsule, soft | 10 mg | Current | Unavailable | Manufacturing | 7/10/2025 |
| isotretinoin | Capsule, soft | 20 mg | Current | Unavailable | Manufacturing | 7/10/2025 |
| enalapril maleate | Tablet | 5 mg | Anticipated | Available | Manufacturing | 7/10/2025 |
| phenobarbital | Tablet, uncoated | 30 mg | Anticipated | Available | Manufacturing | 7/10/2025 |
| metformin hydrochloride | Tablet, film coated | 1000 mg | Current | Unavailable | Manufacturing | 7/10/2025 |
| citalopram hydrobromide | Tablet, film coated | 49.98 mg | Resolved | Available | Manufacturing | 7/10/2025 |
| ezetimibe | Tablet, uncoated | 10 mg | Resolved | Available | Unexpected increase in demand due to other sponsors unable to supply | 7/10/2025 |
| tranexamic acid | Tablet, film coated | 500 mg | Current | Limited Availability | Manufacturing | 7/10/2025 |
| ivabradine hydrochloride | Tablet, film coated | 8.085 mg | Resolved | Available | Manufacturing | 7/10/2025 |
| teriflunomide | Tablet, film coated | 14 mg | Current | Unavailable | Manufacturing | 7/10/2025 |
| pregabalin | Capsule, hard | 300 mg | Anticipated | Available | Manufacturing | 7/10/2025 |
| oseltamivir phosphate | Capsule, hard | 98.524 mg | Current | Limited Availability | Manufacturing | 7/10/2025 |
| sitagliptin hydrochloride monohydrate~metformin hydrochloride | Tablet, modified release | 56.685 mg~1000 mg | Anticipated | Available | Manufacturing | 7/10/2025 |
| Teriparatide | Injection, solution | .25 mg/mL | Current | Limited Availability | Unexpected increase in demand due to other sponsors unable to supply | 7/10/2025 |
| Teriparatide | Injection, solution | 250 microgram/mL | Current | Unavailable | Manufacturing | 7/10/2025 |
| minocycline hydrochloride dihydrate | Tablet, film coated | 54 mg | Resolved | Available | Manufacturing | 7/10/2025 |
| olanzapine | Injection, powder for | 10 mg | Resolved | Available | Unexpected increase in consumer demand | 7/10/2025 |
| ciprofloxacin hydrochloride | Tablet, film coated | 873.32 mg | Current | Limited Availability | Manufacturing | 7/10/2025 |
| methylphenidate hydrochloride | Capsule, modified release | 30 mg | Current | Limited Availability | Manufacturing | 7/10/2025 |
| amoxicillin trihydrate | Oral Liquid, powder for | 28.7 mg/mL | Discontinued | Reduction in supply until supply is exhausted | Commercial Changes / Commercial viability | 6/10/2025 |
2025年10月13日